Skip to main content
. 2021 Sep 15;19:209. doi: 10.1186/s12916-021-02070-w

Fig. 2.

Fig. 2

Hazard ratios for death in non-oncogene positive (A) advanced and/or metastatic NSCLC, (B) ALK-positive and (C) EGFR-positive patients in years 2013 to 2019 relative to 2012, unadjusted, adjusting only for differences in baseline characteristics and adjusting for both baseline characteristics and (A) first and/or second line immunotherapy, (B) first and/or second/third generation ALK inhibitor use, and (C) first/second and/or third generation EGFR inhibitor use